IL-37 exerts direct anti-inflammatory action and blocks nuclear factor kappa B (NF-κB) and mitogen-activated protein kinase (MAPK), reducing tumor growth, angiogenesis, and metastasis. Here, NFKB1 is linked to neoplasm.